<DOC>
	<DOCNO>NCT01638650</DOCNO>
	<brief_summary>This open-label study evaluate safety , pharmacokinetics antiviral activity modify Invirase ( saquinavir ) /ritonavir regimen treatment-naïve HIV-1 infected patient . Patients receive Invirase 500 mg plus ritonavir 100 mg twice daily orally first week , follow Invirase 1000 mg plus ritonavir 100 mg twice daily orally second week . The study treatment give combination two Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) , accordance current clinical HIV treatment guideline . Anticipated time study treatment 14 day .</brief_summary>
	<brief_title>A Study Ritonavir-Boosted Invirase ( Saquinavir ) Treatment-Naïve HIV-1 Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age HIV1 infection Currently treatmentnaïve eligible initiate ritonavirboosted Protease Inhibitor base regimen willing able initiate saquinavir/ritonavir therapy first 14 day ; saquinavir/ritonavir regimen combination two Nucleoside Reverse Transcriptase Inhibitors ( NRTIs ) , accordance current clinical HIV treatment guideline Body mass index 1832 kg/m2 , inclusive Female patient childbearing potential male patient female partner childbearing potential must use 2 method contraception define protocol study least one month last dose study drug Nonsmoker patient stop smoke three month prior Day 1 study Coinfection hepatitis B C ( acute chronic ) Anticipated use need significant concomitant medical treatment study period , background antiretroviral therapy Participation clinical study investigational drug device within 3 month prior Day 1 study Pregnant lactate woman Any clinically relevant history substance abuse addiction include alcohol and/or drug abuse Special dietary restriction would prohibit consumption standardize meal ( e.g . vegetarian , vegan , glutenfree , lactosefree , kosher ) Decompensated liver disease Congenital document acquire QT prolongation Electrolyte disturbance , particularly uncorrected hypokalaemia Clinically relevant bradycardia Clinically relevant heart failure reduce leftventricular ejection fraction Previous history symptomatic arrhythmias History clinically significant gastrointestinal , renal , hepatic , bronchopulmonary , neurological , psychiatric , cardiovascular , endocrinological , , hematological , allergic disease , metabolic disorder , cancer , cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>